Ifinatamab Deruxtecan
Antibody–drug conjugate
Also known as MK-2400
Evidence outlook · registrational
Small Cell Lung Cancer: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2028-01-30. The sponsor reported topline results of a Phase 2 study on 2025-09-07 (IDeate-Lung01 (NCT05280470) Phase 2: confirmed objective response rate 48.2% in 137 previously treated ES-SCLC patients); that is not the registrational readout.
Also in development:Non-Small Cell Lung Cancer · Phase 2Metastatic Castration-Resistant Prostate Cancer · Phase 3Esophageal Squamous Cell Carcinoma · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
IDeate-Lung02 NCT06203210 · Small Cell Lung Cancer Registry: NCT06203210 | 3 | Overall Survival (OS) (From the date of randomization to the date of death due to any cause, up to approximately 3.7 years) 2028-01-30 | In progress: results expected 30 Jan 2028 | not yet graded | link ↗ |
View 1 more trial
IDeate-Lung01 NCT05280470 · Small Cell Lung Cancer Registry: NCT05280470 | 2 | Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC (Up to approximately 36 months) 2025-03-03 | IDeate-Lung01 (single arm, 12 mg/kg, previously treated ES-SCLC): confirmed objective response rate 48.2% (95% CI 39.6-56.9) in 137 patients (Daiichi Sankyo, 7 September 2025). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other B7-H3 drugs
7MW3711, Elfetabart drozuntecan, Risvutatug rezetecan, Tambotatug pelitecan, 177Lu-BetaBart and 1 more. Compare all 7 B7-H3 drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Esophageal Squamous Cell Carcinoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ifinatamab Deruxtecan: this drug | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT03189719: Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590). NCT02564263: Overall survival, pembrolizumab vs investigator's-choice chemotherapy: HR 0.70 (95% CI 0.52 to 0.94) in PD-L1 CPS >=10, HR 0.77 (0.63 to 0.96) in ESCC, HR 0.89 (0.75 to 1.05) in all randomized patients; the label approval is for ESCC with CPS >=10 (KEYTRUDA label, KEYNOTE-181). | |
| Tislelizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT03957590: Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months missed | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Risvutatug Rezetecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Tambotatug Pelitecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab | Phase 2 | Multispecific antibody | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2 | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(17 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ifinatamab Deruxtecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
April 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
2028 (6)
January 2028 (2)
June 2028 (2)
July 2028 (1)
What to watch
November 2028 (1)
What to watch
2029 (1)
February 2029 (1)
What to watch
2030 (1)
November 2030 (1)
What to watch
2031 (2)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent